Torrent Pharma gets USFDA notice for Indrad plant
FDA's official action indicated' classification will not hit supplies, revenues, says Torrent Pharma24-01-2023
24-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is with respect to our earlier communication on September 28, 2022 regarding the USFDA inspection at our manufacturing facility at Indrad, Gujarat and issuance of Form 483 by USFDA with 3 observations. We now wish to inform that the Company has received a communication from the USFDA determining the inspection classification as 'Official Action Indicated' (OAI). This inspection classification will not have impact on existing supplies or revenues from this facility. Torrent Pharma continues to cooperate with the USFDA and will undertake all necessary remedial steps to resolve these issues to the satisfaction of the regulator. Torrent Pharma remains committed to being cGMP compliant quality standards across all its facilities. Please take the information on record.24-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate20-01-2023
Torrent Pharma Q3 PAT seen up 28.9% YoY to Rs 3,211 cr: Nirmal Bang
Net Sales are expected to increase by 14.1 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs 24,020 crore, according to Nirmal Bang.17-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 25th January, 2023 at 05:30 P.M. to discuss the financial performance of the Company for the quarter and nine months ended 31st December, 2022.12-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Intimation Of Record Date Pursuant To Regulation 42 Of The Securities & Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Friday, 3rd February, 2023 as the Record Date for taking record of the Members of the Company for the purpose of payment of Interim Dividend, if declared by the Board at their meeting scheduled to be held on Wednesday, 25th January, 2023.12-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/01/2023 ,inter alia, to consider and approve We would like to inform you that a meeting of the Board of Directors will be held on Wednesday, 25-Jan-23, inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-22. The Board would also consider payment of Interim Dividend for the year 2022-23.12-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement in respect of the transfer of shares to IEPF10-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate05-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window
Pursuant to Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons of the Company (''Code'') and applicable SEBI Regulations, we would like to inform you that trading window for dealing in securities of the Company by Designated Persons stands closed from 1st January, 2023 and will be re-opened 48 hours after the submission of the Financial Results for the Quarter and nine months ended 31st December, 2022 to the Stock Exchanges.28-12-2022